Adenocarcinoma of the Prostate
Showing 1 - 25 of 101
Adenocarcinoma of the Prostate Trial in Montreal (Androgen suppression plus radiation therapy)
Active, not recruiting
- Adenocarcinoma of the Prostate
- Androgen suppression plus radiation therapy
-
Montreal, Quebec, Canada
- +1 more
Jan 30, 2023
Adenocarcinoma of the Prostate Trial in United States (Muscadine Plus, Placebos)
Terminated
- Adenocarcinoma of the Prostate
- Muscadine Plus
- Placebos
-
Duarte, California
- +12 more
Dec 6, 2022
Adenocarcinoma of the Prostate Trial in Washington, Baltimore, Bethesda (Radiation Therapy, Androgen Deprivation Therapy (ADT))
Active, not recruiting
- Adenocarcinoma of the Prostate
- Radiation Therapy
- Androgen Deprivation Therapy (ADT)
-
Washington, District of Columbia
- +2 more
Oct 25, 2022
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer Trial in Beverly Hills, Los Angeles, Pasadena
Active, not recruiting
- Adenocarcinoma of the Prostate
- +5 more
- phenelzine sulfate
- +2 more
-
Beverly Hills, California
- +3 more
Aug 19, 2022
Adenocarcinoma of the Prostate, Stage III Prostate Cancer Trial in Los Angeles (radiation, other, drug)
Active, not recruiting
- Adenocarcinoma of the Prostate
- Stage III Prostate Cancer
- stereotactic body radiation therapy
- +3 more
-
Los Angeles, CaliforniaJonsson Comprehensive Cancer Center
Apr 28, 2022
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage IIA Prostate Cancer Trial in Los Angeles (behavioral, dietary
Active, not recruiting
- Adenocarcinoma of the Prostate
- +3 more
- behavioral dietary intervention
- +2 more
-
Los Angeles, CaliforniaJonsson Comprehensive Cancer Center
Apr 4, 2022
Adenocarcinoma of the Prostate Trial in Jacksonville (HR-A, HR-B)
Recruiting
- Adenocarcinoma of the Prostate
- HR-A
- HR-B
-
Jacksonville, FloridaUniversity of Florida Health Proton Therapy Institute
Mar 14, 2022
Adenocarcinoma of the Prostate, Stage IIB Prostate Cancer, Stage III Prostate Cancer Trial in Duarte (biological, procedure,
Active, not recruiting
- Adenocarcinoma of the Prostate
- +3 more
- anti-PSMA monoclonal antibody MDX1201-A488
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 17, 2022
Prostate Cancer, Adenocarcinoma of the Prostate Trial in Providence (Olaparib Pill, Prostatectomy)
Terminated
- Prostate Cancer
- Adenocarcinoma of the Prostate
- Olaparib Pill
- Prostatectomy
-
Providence, Rhode IslandLifespan Cancer Institute: The Miriam and Rhode Island Hospitals
Feb 2, 2022
Adenocarcinoma of the Prostate Trial in United States (Enzalutamide, SRT)
Active, not recruiting
- Adenocarcinoma of the Prostate
- Enzalutamide
- SRT
-
Washington, District of Columbia
- +8 more
Feb 3, 2022
Adenocarcinoma of the Prostate Trial in United States (sipuleucel-T)
Active, not recruiting
- Adenocarcinoma of the Prostate
- sipuleucel-T
-
Gilbert, Arizona
- +55 more
Jan 18, 2022
Prediction of Lymph Node Invasion for Prostate Adenocarcinoma
Recruiting
- Adenocarcinoma of the Prostate
-
Brest, FranceCHRU Brest
Jan 17, 2022
Prostate Cancer, Adenocarcinoma of the Prostate Trial in Baltimore (Brachytherapy)
Active, not recruiting
- Prostate Cancer
- Adenocarcinoma of the Prostate
- Brachytherapy
-
Baltimore, MarylandThe SKCCC at Johns Hopkins
Nov 4, 2021
Adenocarcinoma of the Prostate Trial in Sacramento (Stereotactic Radiosurgical Boost, Casodex, Leuprolide)
Recruiting
- Adenocarcinoma of the Prostate
- Stereotactic Radiosurgical Boost
- +2 more
-
Sacramento, CaliforniaUC Davis Sacramento Cancer Center Dept of Radiation Oncology
Sep 24, 2021
Circulating Prostate Cells Among Adenocarcinoma Patients
Active, not recruiting
- Adenocarcinoma of the Prostate
- EPISPOT detection of the number of circulating cells
- CellSearch detection of the number of circulating, functional, prostate cells
-
Nîmes Cedex 09, Gard, France
- +4 more
Aug 4, 2021
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer Trial in Detroit (drug, radiation,
Completed
- Adenocarcinoma of the Prostate
- +3 more
- cabozantinib-s-malate
- +4 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Aug 3, 2021
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer Trial in Los Angeles (dietary supplement,
Completed
- Adenocarcinoma of the Prostate
- +6 more
- green tea extract
- +4 more
-
Los Angeles, California
- +1 more
Jun 22, 2021
Adenocarcinoma of the Prostate Trial in Dijon (Stereotactic Radiotherapy with Linac MRI)
Recruiting
- Adenocarcinoma of the Prostate
- Stereotactic Radiotherapy with Linac MRI
-
Dijon, FranceCentre Georges François Leclerc
May 27, 2021
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer Trial in Detroit (docetaxel,
Completed
- Adenocarcinoma of the Prostate
- +3 more
- docetaxel
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Mar 2, 2021
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer Trial in Birmingham, Detroit, Columbus
Active, not recruiting
- Adenocarcinoma of the Prostate
- +2 more
- enzalutamide
- +5 more
-
Birmingham, Alabama
- +3 more
Mar 2, 2021
Adenocarcinoma of the Prostate Trial in United Kingdom (Active CTC Assessment)
Terminated
- Adenocarcinoma of the Prostate
- Active CTC Assessment
-
Sutton, Surrey, United Kingdom
- +3 more
Jan 5, 2021
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer Trial in Orange (Docetaxel, Lycopene)
Completed
- Adenocarcinoma of the Prostate
- +5 more
- Docetaxel
- Lycopene
-
Orange, CaliforniaChao Family Comprehensive Cancer Center
Dec 30, 2020
Prostate Cancer, Adenocarcinoma of the Prostate, Locally Advanced Prostate Carcinoma Trial in Belgium (standard of care)
Recruiting
- Prostate Cancer
- +3 more
- standard of care
-
Dendermonde, Oost-Vlaanderen, Belgium
- +3 more
Jan 4, 2021
Metastatic Castration-resistant Prostate Cancer, Adenocarcinoma of the Prostate Trial in Pécs (Selegiline, Docetaxel)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- Adenocarcinoma of the Prostate
-
Pécs, Baranya, HungaryUniversity of Pécs, Clinical Centre, Department of Oncotherapy
Oct 7, 2020